Brentuximab Vedotin
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Brentuximab Vedotin |
| DrugBank ID | DB08870 |
| Brand Names (EU) | Adcetris |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 99.89% |
Approved Indication (EMA)
Hodgkin lymphomaAdcetris is indicated for adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).Adcetris is indicated for adult patients with previously untreated CD30+ Stage IIB with risk factors, Stage III or Stage IV HL in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD).Adcetris is indicated for the treatment of adult patients with CD30+ HL at increased ri
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | follicular lymphoma | 99.89% | DL |
| 2 | myeloid leukemia | 99.76% | DL |
| 3 | Hodgkins lymphoma | 99.76% | DL |
| 4 | acute lymphoblastic/lymphocytic leukemia | 99.65% | DL |
| 5 | B-cell neoplasm | 99.60% | DL |
| 6 | pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | 99.46% | DL |
| 7 | chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | 99.46% | DL |
| 8 | Richter syndrome | 99.38% | DL |
| 9 | mantle cell lymphoma | 99.32% | DL |
| 10 | ganglioneuroblastoma (disease) | 99.23% | DL |
| 11 | vertebral anomalies and variable endocrine and T-cell dysfunction | 99.16% | DL |
| 12 | lymphoid neoplasm | 99.15% | DL |
| 13 | retroperitoneal neoplasm | 99.14% | DL |
| 14 | lymphoma, non-Hodgkin, familial | 99.02% | DL |
| 15 | neuroblastoma | 98.97% | DL |
| 16 | neoplasm of mature B-cells | 98.94% | DL |
| 17 | B-cell prolymphocytic leukemia | 98.90% | DL |
| 18 | metastatic neoplasm | 98.86% | DL |
| 19 | plasma cell neoplasm | 98.86% | DL |
| 20 | malignant spiradenoma | 98.84% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.